Molecular Health Opens Berlin Office to Support Growing Demand for Digital Health Solutions

Company Strengthens Relationships With Policy Makers and Patient Advocacy Groups


HEIDELBERG, Germany, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Molecular Health, a leader in cloud-based healthcare decision support technology to enable evidence-based treatment decisions and improved outcomes, today announced that the company has opened an office in Berlin, Germany to accelerate the growing European demand for its suite of digital health solutions.

Located on Friedrichstrasse in downtown Berlin close to the government district, the new office reflects Molecular Health's continued corporate growth and will enable the company to further strengthen its relationships with policy makers and patient advocacy groups in Germany.

Renowned guests at the opening event on November 12, 2015 included Prof. Dr. Christiane Woopen, Chairman of the German Ethics Council and an expert in genome analysis, and Dr. Friedrich von Bohlen, Founder and Chairman of the Board of Molecular Health.

Lutz Voelker, CEO of Molecular Health, said, "The opening of our Berlin office is another important milestone in our global commercial strategy. Our presence in Berlin allows continued interactions with key stakeholders across healthcare and the regulatory landscape in Germany. As patient advocacy organizations, healthcare policy makers and payers continue to adopt digital health solutions, we are ideally positioned to accelerate technology-driven healthcare decision making in Germany."

About Molecular Health

Molecular Health is a leading biomedical company that is transforming molecular data and medical knowledge into actionable clinical information for more efficient and safe targeted therapies for each individual patient. Molecular Health generates individualized analysis and clinical interpretation for evidence-based targeted therapy identification utilizing published medical knowledge in a clinical context. In Europe, Molecular Health has the first registered medical device of its kind for personalized cancer medicine. Molecular Health Inc., headquartered in Boston, MA, with a laboratory and support center in Greater Houston, TX, is a wholly owned subsidiary of Molecular Health GmbH, headquartered in Heidelberg, Germany. To learn more, please visit: www.molecularhealth.com



            

Contact Data